Free webinar: Preparing for FDA cGMP Facility Inspections

AHPA Alerts

AHPA Alerts

AHPA keeps members and the industry informed of recent news and developments that impact the trade through email alerts. Subscribe to news as it happens or a weekly summary of all alerts.

Subscribe

View recent alerts:

  • Legal Alerts News on dietary supplement laws, regulations and enforcement
  • Science Alerts The latest research on herbs and botanicals
  • Market Alerts Herbal market trends and AHPA-member press releases
  • Media Alerts Media coverage of the herbal industry 
  • Cannabis Alerts The latest research and news about hemp, CBD and medical marijuana
  • Cosmetic Alerts Regulatory updates and personal care product news

Subscribe to AHPA Updates to stay informed about the latest AHPA news and resources.

Recent News

Free webinar: Preparing for FDA cGMP Facility Inspections

Presented December 17, 2019

Published: Sunday, April 19, 2020

   
 

Event Details

Recorded: Dec. 17, 2019

Duration: 2 hours

Cost: Free

This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of recent FDA inspections. This knowledge will assist businesses in better allocating and directing their compliance resources. 

Industry experts discuss recent FDA inspections, provide an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA warning letter. A veteran industry legal expert provides an insider’s view of the current cGMP enforcement landscape and strategies for compliance.

AHPA staff will offer a detailed analysis of the association’s repository of inspection data, widely regarded as the most in-depth in the industry. This includes data compiled from FDA 483 inspection reports, observation forms, and establishment inspection reports (EIRs). Strategies for companies to effectively respond to an FDA 483 in order to avoid getting a warning letter will be offered, and tips for conducting an FDA inspection are also provided.

Topics

  • Own label distributors and contract manufacturers: What are the differences and what aspects of the cGMP are you responsible for during an inspection?
  • FDA inspection practices and what should be done to prepare
  • Detailed analysis of recent FDA inspection reports
  • Effectively responding to an FDA 483 so as to avoid a Warning Letter
  • FDA inspection do’s and don’ts

Answers to your questions

A 20-30-minute Q&A session follows the speaker presentations to answer attendees' specific questions. Submit your questions before the live event via email to Natasha Weaver.

Presenters

  • Marian Boardley, Owner, Marian Boardley Consulting LLC 
  • Will Woodlee, Esq., Partner, Kleinfeld, Kaplan & Becker LLP & AHPA General Counsel
  • Merle Zimmermann, Ph.D., Chief Information Analyst, American Herbal Products Association (AHPA)

Materials

  • Webinar recording
  • Presenter slides
  • cGMP compliance resources
Print

More links

  • Order Now!Link to download will be emailed to you

2022 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.